Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.

Yenny AngelaSebastian HaferkampCarsten WeishauptSelma UgurelJürgen C BeckerFlorian OberndörferVesna AlarImke SatzgerRalf Gutzmer

Published in: Cancer immunology, immunotherapy : CII (2019)

The combination therapy of metastatic melanoma with PD-1i and denosumab was feasible without unexpected safety issues and showed a promising efficacy signal. Further investigation in prospective studies is needed.

Keyphrases

combination therapy
bone mineral density
giant cell
postmenopausal women
body composition
case control